Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

First Posted Date: 2014-12-04

Last Posted Date: 2025-01-09

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT02307812

A Study of Galunisertib on the Immune System in Participants With Cancer

Phase 1

Completed

Conditions: Neoplasm

Interventions: Drug: Galunisertib

First Posted Date: 2014-12-02

Last Posted Date: 2016-10-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT02304419

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York City, New York, United States

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2963016
Drug: LANTUS®
Drug: Oral Antihyperglycemic Medication

First Posted Date: 2014-11-27

Last Posted Date: 2017-10-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 493

Registration Number: NCT02302716

Locations: 🇺🇸
Manhattan Medical Research, New York, New York, United States
🇺🇸
Atlanta Vanguard Medical Associates, Smyrna, Georgia, United States
🇺🇸
New Horizon Research Center, Miami, Florida, United States

and more 10 locations

A Study of LY2623091 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2623091
Drug: Tadalafil
Drug: Simvastatin
Drug: Itraconazole
Drug: Diltiazem

First Posted Date: 2014-11-24

Last Posted Date: 2020-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT02300259

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of Lispro Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lispro

First Posted Date: 2014-11-18

Last Posted Date: 2015-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT02293551

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore

A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Evacetrapib Tablet
Drug: Evacetrapib Intravenous

First Posted Date: 2014-10-22

Last Posted Date: 2019-03-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 8

Registration Number: NCT02271425

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Phase 1

Completed

Conditions: Neoplasms
Neoplasm Metastasis

Interventions: Drug: LY3022855

First Posted Date: 2014-10-16

Last Posted Date: 2024-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT02265536

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Baricitinib

First Posted Date: 2014-10-16

Last Posted Date: 2019-09-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 290

Registration Number: NCT02265705

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., ZhuZhou, China

A Study of Baricitinib in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Baricitinib

First Posted Date: 2014-10-13

Last Posted Date: 2017-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT02263911

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Tokyo, Japan

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Phase 3

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: Evacetrapib
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2018-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT02260635

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy